NAS
PTGX icon

Nykredit A/S’s Protagonist Therapeutics PTGX Stock Holding History

Nykredit A/S’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$296K Buy
+2,415
New +$252K ﹤0.01% 872

Other funds holding PTGX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $799M AUM 253.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Nykredit A/S's PTGX Position: Q2 2026 in Review

Nykredit A/S opened a new position in Protagonist Therapeutics (PTGX) in Q2 2026: 2,415 shares worth $296K. The stake represents ﹤0.01% of the portfolio and ranks #872 among its holdings.

244 funds tracked by Wall St. Rank hold PTGX as of Q2 2026.

  • Nykredit A/S held 2,415 shares of Protagonist Therapeutics worth $296K as of Q2 2026.
  • Protagonist Therapeutics was a new Nykredit A/S position in Q2 2026.
  • Protagonist Therapeutics made up ﹤0.01% of Nykredit A/S's portfolio in Q2 2026, its #872 holding.
  • 244 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2026.

Based on Nykredit A/S's 13F filing for Q2 2026, filed 13 Aug 2026.